Ranibizumab: the evidence of its therapeutic value in neovascular age-related macular degeneration.

ABSTRACT:

Introduction

Neovascular age-related macular degeneration (AMD) is the leading cause of severe, irreversible visual impairment in people over 60 years of age. Neovascular AMD is characterized by abnormal growth of blood vessels under the retina, specifically the macula. These vessels leak blood and fluids, damaging the retina and its photoreceptors, resulting in permanent loss of central vision. Vascular endothelial growth factor-A (VEGF-A) has been shown to play a critical role in the pathogenesis of neovascular AMD. In the US, ranibizumab, a VEGF-A blocker, is approved and indicated for the treatment of patients with neovascular AMD.

Aims

To review the clinical evidence for ranibizumab in the treatment of neovascular AMD.

Evidence review

Phase III clinical trial dat

SUBMITTER: Kaiser PK 

PROVIDER: S-EPMC3012443 | biostudies-literature | 2008 Jul

REPOSITORIES: biostudies-literature